M PHARMACEUTICAL INC Inactive Instrument
M Pharmaceutical Inc Share Price Deutsche Boerse AG
Equities
CA55346E2050
Biotechnology & Medical Research
| Sales 2018 | 0.75 0.7 59.87 | Sales 2019 | 0.71 0.66 56.6 | Capitalization | 3.53M 3.27M 281M |
|---|---|---|---|---|---|
| Net income 2018 | -5M -4.64M -399M | Net income 2019 | -1M -928K -79.81M | EV / Sales 2018 | 4,852,616 x |
| Net Debt 2018 | 319K 296K 25.46M | Net Debt 2019 | 848K 787K 67.66M | EV / Sales 2019 | 6,168,166 x |
| P/E ratio 2018 |
-0.6
x | P/E ratio 2019 |
-1.97
x | Employees | - |
| Yield 2018 * |
-
| Yield 2019 |
-
| Free-Float | 72.04% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 02/01/18 | |
Robert Payment
DFI | Director of Finance/CFO | 42 | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Skeith
BRD | Director/Board Member | 69 | 30/11/14 |
William Rodgers
BRD | Director/Board Member | - | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
Callitas Health Inc is a Canada-based company that is primarily engaged in integrated clinical-stage pharmaceutical development and over-the-counter (OTC) consumer goods marketing. The Company provides biomedical technologies and products. The Company offers drug treatments for obesity, infertility, intimacy issues, weight management, female sexual dysfunction solutions and women wellness.
| 1st Jan change | Capi. | |
|---|---|---|
| +18.53% | 47.02B | |
| +48.77% | 41.86B | |
| +1.39% | 41.76B | |
| -4.27% | 28.8B | |
| +11.32% | 26.05B | |
| -21.16% | 19.15B | |
| +4.69% | 12.55B | |
| +27.68% | 12.34B | |
| -3.57% | 11.82B |
